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Laboratory-Based Coagulation Tests and Other Blood Sample Analyses
Blood was collected and arterial blood gas analysis was performed before the first oral dose of dabigatran (baseline), after the last oral dose of dabigatran (-90) , after the infusion of dabigatran (0), and 20, 60, 80, 120, 180, 240 and 300 minutes after the first liver injury (Figure 1) . For animals dying before 300 minutes, the last assessment was performed immediately after death.
Blood gases were measured on a blood gas analyzer (ABL700, Radiometer, Copenhagen, Denmark) using heparinized blood samples. Hemoglobin and platelets were measured in samples collected in potassium-EDTA-anticoagulant tubes (1.9 mg/mL final concentration, Sarstedt, Nuembrecht, Germany) using a standard hematology analyzer (MEK-6108, Nihon Kohden, Rosbach, Germany). For coagulation assays and measurement of plasma drug concentrations, blood was collected in 3.2% sodium citrate (Sarstedt) and potassium-EDTAanticoagulant (1.9 mg/mL final concentration, Sarstedt), respectively, centrifuged to obtain platelet poor plasma and stored at -80°C until assayed. Prothrombin time (PT, Innovin and bound HRP-conjugate was detected with tetramethyl benzidine, which was read colorimetrically on a plate reader. Using similar methodology to a previous study performed in humans, 5 the ELISA assay was used to quantify idarucizumab concentrations in potassium-EDTA pig plasma over the validated concentration range (0.1-0.8 µg/mL) with a lower limit of quantification of 0.1 µg/mL.
Whole-Blood Assays: Thromboelastometry and Activated Clotting Time
Whole-blood thromboelastometry was performed on a ROTEM analyzer (TEM International GmbH, Munich, Germany) according to the manufacturer's instructions using blood samples collected in 3.2% sodium citrate. An extrinsically activated assay using recombinant tissue factor (EXTEM) and an intrinsically activated test using ellagic acid and phospholipids Whole-blood samples were collected for measurement of activated clotting time (ACT) using an i-STAT point-of-care device (Abbott, Princeton, NJ) with celite cartridges.
Thrombin Generation
Thrombin generation was determined in plasma using calibrated automated thrombinography (Thrombinoscope BV, Maastricht, The Netherlands) using 5 pM tissue factor. 6, 7 Thrombin generation curves were generated using Thrombinoscope software (version 4, Thrombinoscope BV) to determine endogenous thrombin potential (ETP), lag time and peak thrombin formation. Prolonged lag time values that could not be detected by the software were defined as having a value of 12 minutes for data analysis.
Statistical Analysis
Statistical analysis was performed using SPSS 22 (SPSS, Chicago, IL), and GraphPad Prism (Version 6.0h, GraphPad Software, La Jolla, USA) was used for graphing purposes.
